


# ΔVΔNOS

## 2022 CORPORATE CITIZENSHIP REPORT



# TABLE OF CONTENTS

<b>CEO LETTER</b>	2
<b>ABOUT AVANOS</b>	3
<b>ETHICS</b>	4
Governance	
Compliance	
Political Spending and Lobbying	
Protecting Human Rights	
<b>EMPLOYEES</b>	6
Demographics	
Diversity, Equity & Inclusion	
Human Rights	
Employee Engagement	
Employee Wellness	
Employee Retention	
Compensation	
Occupational Health and Safety	
Training and Educational Opportunities	
<b>SUPPLIERS</b>	10
Corporate Social Compliance	
Conflict Minerals Reporting	
<b>COMMUNITIES</b>	11
Community Relations	
Charitable Giving	
<b>PRODUCTS</b>	12
Supply Chain	
Raw Materials	
Quality	
Packaging	
Unique Device Identification	
Electronic Instructions for Use	
<b>ENVIRONMENTAL</b>	15
Managing Waste	
Managing Greenhouse Gas Emissions	
Managing Water Use	

# A MESSAGE FROM THE CEO

---

One of the things that makes me most proud of Avanos is the integrity our employees demonstrate every single day.

While abiding by established laws and regulations is imperative to operating in the medical device space, it's our employees' genuine commitment to behaving ethically and doing the right thing that continues to fortify our reputation as a good corporate citizen. With this mindset serving as our guide, meeting our obligations is not a challenge, but rather, simply the way we conduct business.

In 2022, we announced the launch of a transformative three-year plan to simplify our business, make work easier and create sustainable value for our internal and external stakeholders. We began by identifying areas for improvement, waste reduction and savings. We then restructured our organization to combine our North America Chronic Care and Pain franchises to drive a consistent, streamlined strategy for our customers.

Internally, we continued to build on the foundation established by our Diversity, Equity & Inclusion (DE&I) Council with a formal charter, pillars and six new employee resource groups (ERGs). These ERGs represent team members whose shared characteristics, experiences or goals promote education and awareness of specific needs within our employee communities.

We also launched a new charitable giving program that gives our employees a greater voice in deciding which organizations Avanos supports with monetary donations. And, in 2022, employees in the US more than doubled their participation in our Matching Gifts program, in which Avanos matches employee donations to qualified charitable organizations dollar-for-dollar.

Operating as a respected global corporate citizen paves the way for us to achieve our vision of being the best at getting patients back to the things that matter.

Thank you for your interest in Avanos. I'm pleased to share this report with you!



A handwritten signature in black ink that reads "Joe L. Woody". The signature is fluid and cursive, written in a professional style.

Joseph F. Woody  
Chief Executive Officer  
Avanos Medical

# ABOUT ΔVΔNOS

---

This report covers the period of Jan. 1 through Dec. 31, 2022.

## OVERVIEW

Avanos is a medical technology company focused on delivering clinically superior medical device solutions that will help patients get back to the things that matter. We are committed to addressing some of today's most important healthcare needs, including providing a vital lifeline for nutrition to patients from hospital to home, and reducing the use of opioids while helping patients move from surgery to recovery.

We develop, manufacture and market our recognized brands globally and hold leading market positions in multiple categories across our portfolio. With corporate headquarters in Alpharetta, Georgia, Avanos operates six principal medical device production facilities, employing more than 4,000 people worldwide. 2022 net revenue was \$820 million.

Avanos Medical Inc. is traded on the New York Stock Exchange under the ticker symbol AVNS.

## BUSINESS

Our business has two franchises: Chronic Care and Pain Management. Each franchise is supported by a dedicated sales force; a customer support team with significant industry experience and robust product training; and customer education programs. Avanos is vertically integrated, manufactures most of its products, and continues to invest in R&D to enhance the effectiveness, reliability and safety of our existing products, as well as to commercialize new products.

## GOVERNANCE

Our culture is based on our commitment to operate ethically and in compliance with applicable global laws and regulations. Our governance for overseeing and managing our business includes:

- a board of directors that is 83% independent
- a clear reporting structure and lines of accountability
- a global code of conduct
- a comprehensive policy platform, including policies on human rights, labor, diversity and inclusion, and environmental issues
- oversight on key environmental, social and governance (ESG) issues

Board Diversity Overview	2022	% of Total as of December 2022
Independent members	5	83%
Women	2	33%
Ethnically diverse membership	1	17%
Total board members	6	

Avanos' board of directors provides oversight and guidance on all aspects of our businesses and relationships with stakeholders. Our annual proxy statement contains detailed information on our board and committee structure, the independence of the members, and the responsibilities and meeting frequency of the board and each committee. The board has established the following standing committees: audit, compensation, compliance and governance. Each committee is responsible for reviewing policies on matters relevant to that committee.

Avanos has a robust compliance and ethics program, overseen by the board's Compliance Committee, the Management Compliance Oversight Committee, our Chief Ethics and Compliance Officer, our Senior Vice President - Quality, and our Senior Vice President - Regulatory and Clinical Affairs.

Key components of that program include: our quality and regulatory policies and procedures, which are designed to ensure compliance with applicable laws and regulations; and our anti-corruption policies and procedures, which are designed to ensure compliance with global anti-corruption standards, including the United States Foreign Corrupt Practices Act and the United Kingdom Bribery Act.

## COMPLIANCE

The development, manufacturing, marketing, sale, promotion and distribution of Avanos products are subject to comprehensive government regulation. Government regulation by various national, regional, federal, state and local agencies, both in the United States and other countries, addresses (among other matters) inspection of, and controls over, research and laboratory procedures, clinical investigations, product approvals and manufacturing, labeling, packaging, marketing and promotion, pricing and reimbursement, sampling, distribution, quality control, post-market surveillance, record keeping, storage and disposal practices.

## COMPLIANCE continued

Avanos operations are also affected by trade regulations in many countries that limit the import of raw materials and finished products, and bylaws and regulations that seek to prevent corruption and bribery in the marketplace (including the United States Foreign Corrupt Practices Act and the United Kingdom Bribery Act, which regulate corporate interactions with government officials), as well as regulations that require safeguards for the protection of personal data. In addition, Avanos is subject to laws and regulations pertaining to healthcare fraud and abuse, including state and federal anti-kickback and false claims laws in the United States. The Physician Payment Sunshine Act, and comparable laws in other jurisdictions, also require Avanos and other manufacturers to annually report payments and items of value given to hospitals and doctors.

Not only does Avanos take its legal obligations seriously, the commitment to compliance is part of our culture, and we seek to engage in ethical decision-making that will contribute to the larger global economy. Avanos has a separate Ethics & Compliance department that reports directly to the Chief Executive Officer and the Compliance Committee of the Board of Directors.

## POLITICAL SPENDING AND LOBBYING

In 2022, Avanos engaged the consulting firm ADVI to advise and represent the company on Medicare coverage and payment policy issues tied to the opioid issue. Avanos is also a member of AdvaMed, a medical device industry association, which lobbies on behalf of its members.

Avanos does not currently operate a political action committee (PAC) in the United States or elsewhere. Similarly, the company makes no contributions to political candidates, PACs that contribute to candidates, or other organizations formed solely for the election or defeat of a public official in the United States or elsewhere.

## PROTECTING HUMAN RIGHTS

We respect international social compliance and environmental principles aimed at promoting and protecting human rights and the environment. Avanos also promotes human rights in our supply chain through our Supplier Social Compliance Standards. The standards are designed to identify, prevent, mitigate and account for human rights violations, with a focus on countries at high risk for human rights abuses.

Our board of directors' Audit and Compliance Committees oversee our efforts to ensure compliance with the Avanos Code of Conduct, other internal policies and certain legal and regulatory requirements.

Compliance with the Avanos Code of Conduct and our Supplier Social Compliance Standards is also verified by an external auditor on an annual basis, in accordance with the United Kingdom Labor Standards Assurance System (LSAS). The LSAS framework is a review of the company's policies, procedures and practices used to identify labor standards abuses, mitigate risks, and drive improvement within the company and with certain external supply chain vendors. An external audit confirmed Avanos' compliance to the LSAS Level 3 requirements for 2022.

# EMPLOYEES

## DEMOGRAPHICS

Employees are our most-valued resource and are at the center of everything we do. Their talent, diversity and commitment are crucial to our innovation and success. Our work environment fosters personal, professional and corporate growth and nurtures innovation through product development and customer solutions. Our global teams work together in a spirit of cooperation to improve health and healthcare every day.

Global Employees	2022	% of Total
APAC	118	2.9%
EMEA	101	2.5%
Latin America	2,861	70.7%
North America	964	23.8%
<b>TOTAL</b>	<b>4,044</b>	

Employee demographics represent the count as of Dec. 31, 2022

## DIVERSITY, EQUITY & INCLUSION

Avanos' commitment to diversity, equity & inclusion (DE&I) supports the company's Mission of delivering breakthrough medical device solutions to improve quality of life through a diverse and inclusive workforce.

Our commitment is also reflected in the important role our DE&I Council plays in our governance practices. Founded in 2021, the DE&I Council comprises employees from various professional grade levels, functional departments and geographic regions throughout Avanos and plays a critical role by:

- implementing Avanos' DE&I strategy and policies while contributing to our growth
- ensuring that DE&I is an integral part of the Avanos culture
- providing governance and oversight with respect to our DE&I endeavors
- advising senior leadership on Avanos' DE&I strategies to ensure they are in alignment with our overall business strategy
- recommending actions to implement, enhance and drive accountability for DE&I metrics

In addition, the Council is committed to helping employees feel valued, respected and heard through a variety of initiatives, including our employee resource groups (ERGs).

These ERGs are voluntary, employee-led groups for employees to share their voices, educate their peers, and bring awareness to specific needs within our greater employee communities. Each ERG is sponsored by a member of the Avanos senior leadership team. In 2022, the Council included two ERGs and announced the formation of six more:

- **BRAVE+**: Building Respect and Valuing Equality with LGBTQ+
- **HIPE**: Helping Industry Professionals Excel (launched in 2022)
- **IlluminASIAN**: Supporting Asian/Pacific Islander employees
- **PACT**: Parents and Caregivers Together
- **SERVE**: Serving Veteran Employees
- **The BEAT**: The Black Employees of Avanos Trailblazing
- **UNIDOS**: Supporting Hispanic/Latinx employees
- **WAVE**: Women of Avanos Empowered (launched in 2021)

# EMPLOYEES

## DIVERSITY, EQUITY & INCLUSION continued

Ultimately, the Council aims to strengthen the engagement and motivation of our global workforce through the creation of a highly inclusive environment that allows a greater level of diversity at every level, thus driving better business outcomes.

Our employee profile below reflects results as of Dec. 31, 2022.

Employee Diversity	2022
Women – global director and above <sup>1</sup>	30.2%
Ethnic minorities – US director and above <sup>1</sup>	16.7%
Women – global salaried employees	44.0%
Ethnic minorities – US salaried employees	29.6%

<sup>1</sup>Leaders in director-level position or higher

## HUMAN RIGHTS

The Avanos Human Rights in Employment Policy underscores our commitment to diversity and inclusion. The policy prohibits discrimination and harassment based on race, color, sex, pregnancy, sexual orientation, gender identity, age, religion, creed, national origin, disability, and other categories protected by applicable laws.

Avanos' commitment to protecting human rights is consistent with our respect for one another and our heritage of fairness, honesty and integrity. This commitment is formalized in our Human Rights in Employment Policy as well as the Avanos Code of Conduct. Our policies align with the goals of several international standards, including the International Labour Organization's Declaration on Fundamental Principles and Rights at Work and those of the UN Global Compact.



# EMPLOYEES

---

## EMPLOYEE ENGAGEMENT

Avanos believes that employees who are engaged in their roles, treated as partners in the business and recognized for their efforts, are more satisfied and productive. Our goal is to ensure that each of our more than 4,000 employees understand how they contribute to the company's innovation and growth. We accomplish this through an employee recognition program and ongoing, two-way communications, including town halls, videos and podcasts, that allow employees to engage with and hear directly from Avanos leaders.

## EMPLOYEE WELLNESS

Avanos takes its commitment to the ongoing health and safety of its employees seriously, offering far-reaching health and benefits packages including wellness and awareness programs. Wellness initiatives vary by location but include an Employee Assistance Program (EAP), health assessments, on-site exercise facilities and employer-sponsored challenges that foster healthy habits.

## EMPLOYEE RETENTION

In 2022, Avanos continued a multi-tiered employee retention strategy, including:

- enhanced compensation and rewards, including expanded benefits and continued flexible work arrangements
  - » expanded benefits include 12 weeks of paid parental leave for biological and adoptive parents
- fostering greater employee engagement through initiatives such as employee resource groups, peer-to-peer coaching, internal promotions, a leadership development program and increased interactions with senior leaders
- recognizing employees for their efforts through a variety of awards, spotlights and appreciation events

## COMPENSATION

Avanos compensates employees competitively and fairly in markets throughout the world. Compensation for salaried employees is strongly tied to performance objectives. Salaried employees above a certain pay grade have a substantial portion of their total compensation subject to performance objectives. More about our executive officer compensation can be found in our 2023 proxy statement.

# EMPLOYEES

## OCCUPATIONAL HEALTH AND SAFETY

Avanos has undertaken a detailed plan for risk assessment and mitigation; issuing communications and establishing a metric for safety initiatives based on leading metrics. Our operations leadership and management teams all have a safety component to their annual performance objectives and actively participate in the programs. Our safety goals involve creating total employee awareness, solid risk management and facility/equipment compliance, and high individual accountability for safety. We believe strongly in the recognition and celebration of outstanding achievements in safety.

### 2022 Health and Safety Highlights

5 of 8 locations recorded zero accidents in 2022 and received the Crystal Eagle Award for excellence in safety performance

Equipment risk scores reduced 17% from previous year

Received over 5,200 employee engagement cards in our Avanos Observations Program – a self-reported performance program to improve employee safety, health and environmental processes

Monthly health and safety campaigns at all production sites reduced safety incident rate by 33% – the lowest in Avanos' history

Employee Safety (Calendar Year)	2022
Fatalities	0.00
Permanently disabling injuries	0.00
Total reportable incident rate (TRIR)	0.14
North America	0.14
Europe	0.00
Middle East and Africa	0.00
Lost-time reportable incident rate (LTRIR)	0.14
North America	0.14
Europe	0.00
Middle East and Africa	0.00

## TRAINING AND EDUCATIONAL OPPORTUNITIES

Because Avanos is a medical device manufacturer, employees are regularly trained in key areas required by the FDA and other applicable regulatory authorities, including topics such as documentation, safety, complaint handling, anti-bribery and quality, among others. In addition to regulated training, employees are educated on the Avanos Code of Conduct, and other topics for legal compliance and ethical decision-making, so that all employees align with our cultural and behavioral expectations.

# SUPPLIERS

---

## CORPORATE SOCIAL COMPLIANCE

The Avanos Code of Conduct provides guidance for dealing with our customers, suppliers, employees, competitors and the public with integrity and in an ethical and appropriate manner. In addition to the Code of Conduct, Avanos drives ethical business practices by adopting the AdvaMed Code of Ethics, the MedTech Europe Code of Ethical Business Practice, the APAMed Code of Ethical Conduct, and other regional and local codes of ethics adopted globally in the medical device industry.

We respect international social compliance and environmental principles aimed at promoting and protecting human rights and the environment. We integrate human rights into our direct and contracted operations, as well as through our supplier arrangements. Avanos policies align with the goals of several international standards, including the International Labour Organization's Declaration on Fundamental Principles and Rights at Work. These values are formalized in the Avanos Human Rights in Employment Policy and Instructions.

### SUPPLIER SOCIAL COMPLIANCE STANDARDS

Social compliance is integral to Avanos' workplace accountability programs. These standards are driven by the belief that good corporate citizenship is essential to our long-term business success and must be reflected in our relationships and actions in our workplaces and the workplaces of those who are authorized to directly supply our business.

### DUE DILIGENCE PROCESS

In selecting new, finished-product, contract manufacturing suppliers, Avanos uses a multi-level due diligence process that involves surveys, reviews of supplier policies, procedures, records and background/reference checks.

### CALIFORNIA TRANSPARENCY IN SUPPLY CHAINS ACT DISCLOSURE

Avanos evaluates and addresses risks of human trafficking and slave labor throughout its supply chain. Verification of this process is completed by independent audits and/or self-assessments. During these audits, Avanos receives certification from certain of our direct suppliers that the materials incorporated into their products comply with the laws regarding slavery and human trafficking of the country in which they are doing business.

Avanos' Social Compliance Standards and Code of Conduct are enforced to help maintain internal and external social compliance accountability standards and procedures for suppliers, employees or contractors in regard to combating slavery and human trafficking.

## CONFLICT MINERALS REPORTING

Conflict minerals are tungsten, tin, tantalum and gold, and any other mineral or its derivatives determined by the US Secretary of State to be financing conflict in the Democratic Republic of Congo (DRC) or any country that shares an internationally recognized border with the DRC.

Avanos conducts a reasonable country-of-origin inquiry (RCOI) to determine whether any materials used in our products originated in the DRC or an adjoining country or were from recycled or scrap sources. A summary of our RCOI, as well as the steps taken to exercise due diligence on the source and chain of custody of our product materials, is included in our Conflict Minerals Report, which can be found in our SEC filings.

# COMMUNITIES

---

## COMMUNITY RELATIONS

Avanos strives to improve the well-being of the people we touch through a range of health, humanitarian, economic and environmental initiatives to help sustain the communities where our employees work and live. We maintain strategic partnerships with organizations that address issues related to our business and that are of interest to our employees, customers and global communities.

## CHARITABLE GIVING

Charitable giving is an important part of our corporate citizenship goals, and being a good corporate citizen includes giving to those in need, whether it's providing resources, offering financial support, or donating time to help others.

In 2022, we launched our new "Matters of the Heart" charitable giving and community service program to provide opportunities to do good throughout the year while giving employees a voice in determining which charities would receive a charitable donation from Avanos.

In March, we invited employees to nominate their favorite charitable organizations for consideration. We received nearly 100 recommendations, which our Grants and Donations Committee reviewed and narrowed to 20 qualifying finalists. Employees then voted for their favorite charities, and after tallying the results, we announced the top 10 employee-nominated charitable organizations, each of which received a \$10,000 donation from Avanos:

- Children Incorporated
- Cure Alzheimer's Fund
- Cystic Fibrosis Foundation
- Girls on the Run
- Hire Heroes USA
- One Simple Wish
- Ronald McDonald House Charities, Inc.
- St. Jude Children's Research Hospital
- The Drake House
- Tunnels to Towers

In October, to celebrate Make a Difference Day, we encouraged employees to take the afternoon to support a local charity or social organization, and in December, to celebrate Giving Month, employees took part in a food drive to support the North Fulton Community Charities Food Pantry.

While these were examples of some specific efforts in 2022, every year, Avanos' Matching Gifts program enables global employees to double their personal donations to qualified charitable organizations. Avanos matches all contributions to qualified organizations - such as not-for-profit entities and schools - over \$50 and up to \$1,000 per employee, per year.

# PRODUCTS

---

## SUPPLY CHAIN

Maintaining a responsible and resilient supply chain is a business imperative, and our relationships with suppliers are essential to our ability to deliver on promises to customers and other stakeholders. Avanos seeks to do business with suppliers who share our values of quality, service, fair dealing and our commitment to being a responsible corporate citizen.

The Supplier Social Compliance Standards (SSCS) are a vital pillar of Avanos' supply chain and align with our Code of Conduct and Human Rights in Employment Policy. These standards are driven by the belief that good corporate citizenship is essential to our long-term business success and must be reflected in our relationships and actions in Avanos workplaces and the workplaces of those who are authorized to directly supply our business. The practices reflect the values we uphold in our own policies, and we expect our suppliers to follow these standards and requirements.

## RAW MATERIALS

Avanos uses a wide variety of raw materials and other inputs in our production processes. We base our purchasing decisions on quality assurance, cost-effectiveness and regulatory requirements. We work closely with our suppliers to ensure continuity of supply while maintaining high quality and reliability. We primarily purchase these materials from external suppliers, some of which are single-source suppliers.

Global commodity prices can affect pricing of certain raw materials we use. The prices of resins and finishing supplies often fluctuate in response to changes in oil prices. Prices of these commodities can be volatile and have varied significantly in recent years, contributing to fluctuations in our operating results. More information can be found in our SEC filings.

Avanos relies on product materials and inputs, such as polyethylene and other commodities, in the manufacture of polymer products that are developed and sold globally.

Materials Used (metric ton)	2022
Polymers	1,521

# PRODUCTS

## QUALITY

Ensuring quality is an essential part of Avanos' business strategy, and a culture of quality is the foundation for meeting the expectations of healthcare providers and their patients. It is our policy to design, manufacture, deliver and service products that meet or exceed customer expectations for quality, performance and value. We accomplish this by:

- establishing quality objectives, processes, procedures and practices that meet or exceed customer and regulatory requirements
- establishing accountability for quality systems management
- providing resources necessary to execute the quality management system
- conducting regular assessments of quality systems and practices to promote continuous process, product and service improvement, and to ensure compliance with applicable laws and regulations

External regulations and industry best practices, as well as internally developed standards, define our quality criteria. Programs are established to measure compliance with these and report results to senior management. These quality standards and established quality system processes drive the continuous improvement activities that ensure that Avanos products are safe and effective for customers.

Should they become necessary, product field action/recall programs are in place to promptly address potential product or safety issues. These processes are tested periodically to ensure that they are effective and efficient.

In 2022, the following voluntary field actions/recalls were conducted by Avanos:

Product	Regions
MIC* Bolus Gastrostomy Feeding Tube - 20 Fr	Japan
CORTRAK*2 Enteral Access System (EAS)	Australia, Austria, Canada, Germany, India, Ireland, Japan, Kuwait, Malaysia, Netherlands, New Zealand, Singapore, Switzerland, United Kingdom, United States
CORTRAK*2 Enteral Access System (EAS)	Canada
HOME PUMP C-SERIES* and ON-Q* kits	Malaysia, Singapore, Korea
MIC-KEY* Gastric-Jejunal Feeding tube kit, Extension Sets with ENFit® connectors, Endoscopic/Radiologic Placement	Australia
Medfusion® Syringe Pump Model Series 3500 <i>(Avanos is distributor not legal manufacturer)</i>	United States
MPS Y-CONNECTOR: 6" Small Kink Resistant Tubing Bifurcated Connector/2 Male Luer Locks, 1 Female Luer Lock <i>(Avanos is distributor not legal manufacturer)</i>	United States

Avanos maintains an ongoing commitment to protecting customer health and safety. Our product-safety scientists are trained and accredited in the fields of toxicology, biocompatibility testing and health-risk assessments. Most have doctoral degrees and several are board-certified by the American Board of Toxicology. Safety assessments conducted by our product-safety experts cover the complete life cycle of a product: research and development, manufacture, sale, use and disposal.

# PRODUCTS

## PACKAGING

Our product packaging helps ensure the quality and safe delivery of our products to customers around the world every day. As we focus on continuous improvement, we incorporate sustainable packaging considerations early in the design process, balancing environmental concerns with the need to protect product quality and transport products efficiently and economically. Optimizing packaging designs for patient safety and customer ease of use, while meeting sterilization and supply chain needs, are also key considerations.

## UNIQUE DEVICE IDENTIFICATION

Avanos employs Unique Device Identification (UDI)-compliant labeling.

The UDI system is used to mark and identify medical devices through their distribution and use. This helps reduce medical errors and more quickly identify medical devices in the case of adverse events or recalls, in addition to providing an accessible source of definitive device identification information. Scanning bar codes containing standardized product information not only streamlines recall management and facilitates device data tracking by clinical research registries, but also offers hospitals the opportunity to better manage inventory and integrate standardized product information into their electronic medical records.

Using UDI to document the device(s) in a patient's record improves the accuracy of surveillance and patient care, and furthers our mission to be the best at getting patients back to the things that matter.

## ELECTRONIC INSTRUCTIONS FOR USE

Avanos transitioned all US-based professional use customers from printed paper instructions to Electronic Instructions for Use (eIFU) as another way to reduce our carbon footprint.

With the product, customers can scan a QR code to access a full set of usage instructions through a dedicated website instead of receiving paper packaging inserts. eIFUs provide real-time updates for customers and eliminate the need to store paper instructions when storage space within hospitals and other clinical settings is often minimal.

Paper production, distribution and disposal require a large amount of energy and raw materials. Using eIFUs eliminates over 275 tons of paper consumption annually, as well as oil, water and energy associated with production, distribution and disposal of paper.

### eIFU Sustainability Benefits Contribute to:

Reducing oil consumption by more than <b>100,000 GALLONS</b>	Reducing water consumption by more than <b>2,600,000 GALLONS</b>	Reducing energy consumption by over <b>1,100,000 KILOWATTS</b>
--	--	--

# ENVIRONMENTAL

Striving for clean air, clean water and a healthy environment is fundamental to the way we manufacture our products. We recently upgraded our environmental software to help us define our carbon footprint and report metrics related to waste management, emissions, utilities and regulatory activity in all facilities and buildings within our scope of responsibility for greenhouse gas (GHG) emissions, Scopes 1 and 2.

## MANAGING WASTE

Avanos continues to pursue waste elimination and waste recycling. Our production facilities have been conducting Kaizen events and other Lean methods to reduce scrap and waste in our production processes.

Because managing waste is important to our stakeholders, and because the majority of our products are single use, we have made waste management a key priority.

Nonhazardous Waste (MT)	2022
Incineration without Heat Recovery	85.27
Landfilled	536.28
Permanent Storage	0.97
Reused	0.04
Recycled	1312.54
Waste-to-Energy	0.47
<b>Total Hazardous Waste</b>	<b>1,935.57</b>
<b>Percentage of Non-Hazardous Waste Landfilled</b>	<b>28%</b>

Hazardous Waste (MT)	2022
Blended Fuel	72.69
Chemical Treatment	52.44
Incineration without Heat Recovery	34.73
Permanent Storage	4.67
Recycled	3.32
Thermal Treatment	1.09
Waste-to-Energy	0.87
<b>Total Hazardous Waste</b>	<b>169.81</b>
<b>Percentage of Hazardous Waste Landfilled</b>	<b>0%</b>



# ENVIRONMENTAL

## MANAGING GREENHOUSE GAS EMISSIONS

Our measurements track Scope 1 (direct) emissions, which includes ozone-depleting substances (refrigerants), waste management, stationary and mobile energy consumption. We also track and report Scope 2 (indirect) emissions, which include electricity, and other energy generated off-site and purchased by Avanos. Our production facilities in Mexico partner with the Federal Electricity Commission, our sole electricity provider, to improve energy efficiency at our plants.

Electricity Type 2022 (MW)	2022
Fossil Fuel Electricity Purchased	29,799.95
Carbon-Free Electricity Purchased	1,249.01
Carbon-Free Electricity Generated and Consumed*	152.1
<b>Total Electricity</b>	<b>31,201.05</b>

\*Generated by Photovoltaic system at our Tijuana facility.

Greenhouse Gas Emissions (CO <sub>2</sub> e)	2022
Scope 1 (direct)	1,611.34
Scope 2 (indirect)	13,259.54
<b>Total Emissions (tCO<sub>2</sub>e)</b>	<b>14,870.88</b>

## MANAGING WATER USE

Although water is not utilized in many Avanos processes, water use is measured and recorded for manufacturing and all general business operations, tracking it to its discharge destination. Where we use process water at our facilities, effluent water is returned in accordance with all applicable guidelines.

Water Use [m <sup>3</sup> ]	2022
Total Influent	82,511
Municipal water	63,290
Ground water	19,221
Total Effluent	72,793
Municipal water discharge	72,793